Milestones and announcements.

Clinical progress, funding validation, and manufacturing development across KELI's pipeline.

5 items

12 June 2026

Partnership

KELI Therapeutics Makes its International Investor Debut at bio:cap 2026 in Berlin, Showcasing the First Cell Therapy in Clinical Development for AKI Prevention Following Cardiac Surgery

KELI Therapeutics completed its participation in bio:cap 2026 — the Life Science & AI Investival, held 9–11 June 2026 in Berlin — presenting KELI-101 and its €4.0M convertible loan round to life science investors, biotech industry leaders, and strategic partners from across Europe and beyond, operating from its dedicated exhibition stand at Booth 19A.

25 May 2026

Clinical

KELI Therapeutics Receives EU Clinical Trial Number for MesAKI — the First Phase 1B/2 Trial of a Placental Cell Therapy to Prevent Acute Kidney Injury Following Cardiac Surgery

EU clinical trial number 2026-527099-98-00 was assigned in May 2026. The assigned number is not a submitted or approved Clinical Trial Authorisation application.

External source

June 2025

Funding

KELI Therapeutics Awarded €2.5M EIC Accelerator Grant for KELI-101 AKI Programme

€2.5M EIC Accelerator grant.

25 September 2025

Partnership

KELI Therapeutics and Bramble Bio Announce Manufacturing Partnership to Advance KELI-101

KELI Therapeutics has signed a strategic manufacturing agreement with Bramble Bio (a FamiCord AG CDMO) to support GMP manufacturing scale-up and technology transfer for KELI-101, its placental MSC therapy for acute kidney injury following cardiac surgery. Technology transfer is currently in progress.

External source

March 2026

Clinical

RECARTA Autologous Chondrocyte Therapy: Clinical Delivery Partnership with Gijos Klinikos, Kaunas

RECARTA is approved under EU Hospital Exemption in Lithuania, with product-specific ATMP manufacturing permit No. 25. KELI works with Gijos Klinikos, Kaunas, for clinical delivery.

Media Enquiries

Press and investor relations contact.

For media enquiries, interview requests, or investor relations information, contact the KELI communications team directly.

Press, Media and Investor Relations

info@keli.eu

Patient Enquiries

patients@keli.eu